SINGAPUR, 31 de julio, 2025 /PRNewswire/ -- Emerald Clinical Trials, organización líder mundial en investigación clínica, anunció hoy una transición de liderazgo. Mary Gunn ha dimitido con efecto inmediato. La Junta Directiva ha nombrado a Glenn Kerkhof, miembro de larga trayectoria y...
Hence then, the article about emerald clinical trials confirma el plan de transicion y continuidad de su consejero delegado was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Emerald Clinical Trials confirma el plan de transición y continuidad de su consejero delegado )
Also on site :
- BTQ Technologies Announces New Quantum Hardware Commercialization Hub in New York City and Key Engineering Hires to Accelerate QCIM
- SANY to Unveil New Machines, Smart Technology, and Service at CONEXPO 2026
- Voice of America is covering Iran’s protests, but not its best-known dissident